Cardiovascular Manifestations and Therapy Options for Systemic Lupus Erythematosus: A Systemic Literature Review
DOI:
https://doi.org/10.56570/jimgs.v2i2.114Keywords:
SLE, Lupus, Discoid lupus erythematosus, Autoimmune disease, Hydroxychloroquine٠ Immune suppressive, Anti-malarial, Plaquenil, Pericarditis, Constrictive pericarditis, Diffuse ST elevation, PericardiectomyAbstract
Systemic lupus erythematosus (SLE) is an autoimmune multi-systemic disease; it is a controlled disease but is not curable. SLE affects different systems in the body, such as cardiac, renal, respiratory, hematology, neurology, and rheumatology. It can cause various problems in the heart, lungs, and joints. This Systemic review researched articles from 3 databases: PubMed, Google Scholar, and PubMed Central in June 2022. We did this systemic review using Prisma guidelines. We collected this systemic review in the last five years. Free full articles randomized controlled trial (RCT), systemic review articles, and English language included. Other languages and articles earlier than 2017. Joanna Briggs Institute (JBI) checklist, Assessment of Multiple Systemic Reviews 2 (AMSTAR), and Scale for the Assessment of Multiple Systemic Reviews 2 (SANRA) are used to check for quality assessment. In the systemic review, the initial search generated 516 articles. They included 13 in the final selection; six were case reports, two were systemic reviews, three of them retrospective studies, and two were literature reviews. In this Systemic review, we will focus on the cardiac manifestations associated with systemic lupus erythematosus and use Hydroxychloroquine to prevent the deterioration of systemic lupus erythematosus and decrease the incidence rate cardiac problems. It discovered a decrease in the incidence rate of cardiac manifestations. It found that hydroxychloroquine is effective in the treatment of systemic lupus erythematosus patients. Not only that, but they found that Hydroxychloroquine effectively treats systemic lupus erythematosus patients and limits cardiac risk factors. We need further studies and research to understand the effect of systemic lupus erythematosus on the cardiac system and the effects of Hydroxychloroquine on decreasing the impact of systemic lupus erythematosus on the heart.References
Larson NP, Frawley TC, Long B. Cardiac Tamponade in an-18-year-old Male with Undiagnosed Systemic Lupus Erythematosus. Cureus. 2019;11(7):e5186. Published 2019 Jul 21. doi:10.7759/cureus.5186
Marijanovich N, Halalau A. Hemorrhagic Tamponade as Initial Manifestation of Systemic Lupus with Subsequent Refractory and Progressive Lupus Myocarditis Resulting in Cardiomyopathy and Mitral Regurgitation. Case Rep Rheumatol. 2018; 2018:7635982. Published 2018 Jan 21. doi:10.1155/2018/7635982
Raval, J.J., Ruiz, C.R., Heywood, J. et al. SLE strikes the heart! A rare presentation of SLE myocarditis presenting as cardiogenic shock. BMC Cardiovasc Disord 21, 294 (2021). https://doi.org/10.1186/s12872-021-02102-6
Tariq S, Garg A, Gass A, Aronow WS. Myocarditis due to systemic lupus erythematosus associated with cardiogenic shock. Arch Med Sci. 2018;14(2):460-462. doi:10.5114/aoms.2017.68692
Ezat Amin, M., Elsayed, M., Mohammed, H., Abdel baset, A., Kasem, S. Cardiovascular System involvement in systemic lupus erythematosus (SLE). Sohag Medical Journal, 2021; 25(1): 18-22. doi: 10.21608/smj.2020.41302.1192
Thomas G, Cohen Aubart F, Chiche L, et al. Lupus Myocarditis: Initial Presentation and Longterm Outcomes in a Multicentric Series of 29 Patients. J Rheumatol. 2017;44(1):24-32. doi:10.3899/jrheum.160493
Zhang X, Wu W. Cardiac tamponade as the initial symptom due to systemic lupus erythematosus in a young man: A case report. Medicine (Baltimore). 2018;97(51): e13708. doi:10.1097/MD.0000000000013708
Jawaid A, Almas A. Cardiac tamponade as initial presentation in systemic lupus erythematosus. J Coll Physicians Surg Pak. 2014;24 Suppl 2: S138-S140.
Shimizu T, Murata M, Tomizawa H, Mitsuhashi T, Katsuki T, Shimada K. Systemic lupus erythematosus initially manifesting as acute pericarditis complicating with cardiac tamponade: a case report. J Cardiol. 2007;49(5):273-276.
Maharaj SS, Chang SM. Cardiac tamponade as the initial presentation of systemic lupus erythematosus: a case report and review of the literature. Pediatr Rheumatol Online J. 2015; 13:9. Published 2015 Mar 17. doi:10.1186/s12969-015-0005-0
Cheng W, Balachandar R, Mistry P. Cardiac tamponade: an initial presentation of SLE. BMJ Case Rep. 2013;2013: bcr2013200011. Published 2013 Jul 18. doi:10.1136/bcr-2013-200011
Umer A, Bhatti S, Jawed S. Sub-acute Cardiac Tamponade as an Early Clinical Presentation of Childhood Systemic Lupus Erythematosus: A Case Report. Cureus. 2018;10(10): e3478. Published 2018 Oct 22. doi:10.7759/cureus.3478
Li W, Frohwein T, Ong K. Cardiac tamponade as an initial presentation for systemic lupus erythematosus. Am J Emerg Med. 2017;35(8): 1213.e1-1213.e4. doi: 10.1016/j.ajem.2017.04.075
Murphy G, Isenberg D. Effect of gender on clinical presentation in systemic lupus erythematosus. Rheumatology, Volume 52, Issue 12, December 2013, Pages 2108–2115, doi.org/10.1093/rheumatology/ket160
Meridor K, Shoenfeld Y, Tayer-Shifman O, Levy Y. Lupus acute cardiomyopathy is highly responsive to intravenous immunoglobulin treatment: Case series and literature review. Medicine (Baltimore). 2021;100(18): e25591. doi:10.1097/MD.0000000000025591
PRISMA 2020 Checklist (.pdf)
https://jbi.global/sites/default/files/2021-10/Checklist_for_Case_Reports.docx
https://amstar.ca/Amstar_Checklist.php
https://www.ohri.ca//programs/clinical_epidemiolo gy/nosgen.pdf
https://researchintegrityjournal.biomedcentral.com /articles/10.1186/s41073-019-0064-8
Anis A, Varda M, Dudar A, Schmitz ED. MSSA pericarditis in a patient that was presented with systemic lupus erythematosus flare. Southwest J Pulm Crit Care Sleep. 2022. doi.org/10.13175/swjpccs057-21
Jethwa H, Rana M, Kitt J, Menzies S, Steuer A. Constrictive pericarditis as the first presentation of systemic lupus erythematosus. Rheumatic Dis Treatment J.2019. 1: 10-12. doi.org/10.33805/2694-2216.104
Liu D, Li X, Zhang Y, et al. Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. Drug Des Devel Ther. 2018; 12:1685-1695. Published 2018 Jun 11. doi:10.2147/DDDT.S166893
Hu S, Lin C, Cai X, et al. The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis. Mediators Inflamm. 2021; 2021:7712587. Published 2021 Aug 31. doi:10.1155/2021/7712587
Wakiya R, Kameda T, Nakashima S, et al. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose. Intern Med. 2020;59(17):2105-2112. doi:10.2169/internalmedicine.4317-19
Fernandez-Ruiz R, Bornkamp N, Kim MY, et al. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. Arthritis Res Ther. 2020;22(1):191. Published 2020 Aug 17. doi:10.1186/s13075-020-02282-0
Martinez GP, Zabaleta ME, Di Giulio C, Charris JE, Mijares MR. The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. Curr Pharm Des. 2020;26(35):4467-4485. doi:10.2174/1381612826666200707132920
Narain S, Berman N, Furie R. Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis. Curr Opin Rheumatol. 2020;32(6):609-616. doi:10.1097/BOR.0000000000000754
Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis. 2022; 14:1759720X211073001. Published 2022 Feb 14. doi:10.1177/1759720X211073001
Clowse MEB, Eudy AM, Balevic S, et al. Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus Sci Med. 2022;9(1): e000651. doi:10.1136/lupus-2021-000651
Floris A, Piga M, Mangoni AA, Bortoluzzi A, Erre GL, Cauli A. Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. Mediators Inflamm. 2018; 2018:3424136. Published 2018 Feb 18. doi:10.1155/2018/3424136
Olsen NJ, James JA, Arriens C, et al. Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial. Trials. 2018;19(1):694. Published 2018 Dec 20. doi:10.1186/s13063-018-3076-7
Li XB, Cao NW, Chu XJ, et al. Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies. Ann Med. 2021;53(1):1687-1695. doi:10.1080/07853890.2021.1981547
Cornwell MG, Luttrell-Williams ES, Golpanian M, et al. Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus. Lupus Sci Med. 2021;8(1): e000475. doi:10.1136/lupus-2021-000475
Vázquez-Otero I, Medina-Cintrón N, Arroyo-Ávila M, González-Sepúlveda L, Vilá LM. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus. Lupus Sci Med. 2020;7(1): e000395. doi:10.1136/lupus-2020-000395
Virdis A, Tani C, Duranti E, et al. Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. Arthritis Res Ther. 2015; 17:277. Published 2015 Oct 6. doi:10.1186/s13075-015-0790-3
Petri M, Konig MF, Li J, Goldman DW. Association of Higher Hydroxychloroquine Blood Levels with Reduced Thrombosis Risk in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2021;73(6):997-1004. doi:10.1002/art.41621
Jorge A, McCormick N, Lu N, et al. Hydroxychloroquine and Mortality Among Patients with Systemic Lupus Erythematosus in the General Population. Arthritis Care Res (Hoboken). 2021;73(8):1219-1223. doi:10.1002/acr.24255
